Press Release
Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder Fosrenol® Launches In Europe
BASINGSTOKE, UNITED KINGDOM (25 June 2007) Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ). New data from a patient adherence survey presented on Friday 22nd June at the XLIV ERA-EDTA Congress in Barcelona highlight that over 40% of patients with chronic kidney disease (CKD) forget to take their phosphate-binding medication.1 Phosphate binders are used to treat hyperphosphataemia (unusually high levels of phosphorous in the blood), which, if not managed successfully, can lead to serious health consequences including increased rates of cardiovascular morbidity and mortality and other complications.
To view the full release please click here
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
